Status:

COMPLETED

A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache

Lead Sponsor:

Janssen-Ortho LLC

Collaborating Sponsors:

Ortho-McNeil Neurologics, Inc.

Conditions:

Migraine

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) 12.5 milligram tablets compared with placebo for the acute treatment of migraine headache at the ea...

Detailed Description

Almotriptan malate (AXERT®) is approved for the treatment of migraine headache, with or without aura, in adults. This is a multicenter, randomized, double-blind, placebo-controlled, parallel group stu...

Eligibility Criteria

Inclusion

  • Diagnosis of migraine, with or without aura
  • At least moderate pain with migraines
  • Average of 2 to 6 migraines per month for past 3 months
  • Duration of headache pain at least 4 hours
  • Able to tell the difference between a migraine and a tension headache
  • If taking a medication to prevent migraines, patients must have been taking a maintenance dose for at least 30 days before screening
  • In generally good health
  • If female, using birth control

Exclusion

  • Routinely experience other type of headache that might seem like a migraine headache
  • An average of 15 or more headache days per month in the past 6 months
  • Migraines began after age 50
  • Taking \> 1 medicine for preventing migraines
  • Use of any drugs on list of prohibited drugs, of opioid drugs in past 7 days, of corticosteroids in the past 30 days, of an investigational drug within 30 days
  • Use of non-drug treatment for migraine in past 14 days unless have used this treatment for \> 14 days and plan to continue throughout study
  • Overuse of medications that treat pain or nausea
  • Migraine aura without headache
  • Hemiplegic or basilar migraines
  • Usually have vomiting with headache
  • Headaches that usually occur upon waking
  • Significant unstable medical disease
  • Abnormal liver, kidney, blood, or ECG laboratory or test results
  • Abusing drugs or alcohol
  • History of a significant mental disorder
  • Pregnant or breast-feeding

Key Trial Info

Start Date :

November 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2005

Estimated Enrollment :

378 Patients enrolled

Trial Details

Trial ID

NCT00210509

Start Date

November 1 2004

End Date

June 1 2005

Last Update

May 17 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.